Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy
Restelli, Umberto, Alberti, Alfredo, Lazzarin, Adriano, Bonfanti, Marzia, Nappi, Carmela, Croce, DavideМова:
english
Журнал:
The European Journal of Health Economics
DOI:
10.1007/s10198-016-0865-3
Date:
December, 2016
Файл:
PDF, 522 KB
english, 2016